CNS-TB, although less common than pulmonary tuberculosis, is far more lethal and debilitating due to its involvement with critical neural tissue. Traditionally, treatment has relied on antitubercular drugs aimed at eradicating Mycobacterium tuberculosis bacteria, yet patients consistently experience high mortality and often develop lasting neurological impairments. This new research identifies a pathophysiological basis underlying these clinical challenges, shifting the focus towards mitigating the host immune response that damages the central nervous system.

The team, led by Associate Professor Catherine Ong Wei Min from the Infectious Diseases Translational Research Programme at NUS Medicine, undertook a rigorous investigation into the prognostic factors influencing CNS-TB outcomes. Cerebrospinal fluid samples derived from 72 pediatric patients diagnosed with tuberculous meningitis were meticulously analyzed alongside controls. This analysis uncovered markedly elevated levels of matrix metalloproteinases (MMPs) — enzymes known for degrading extracellular matrix components — and neutrophil extracellular traps (NETs), which are networks of DNA and proteins expelled by immune cells in response to infection. The concurrent presence of these molecules appears to exacerbate tissue destruction and inflammatory damage within the brain.

Recognition of these harmful mediators led researchers to hypothesize that dampening their activity could alleviate CNS-TB severity. To evaluate this, the team innovatively developed laboratory models of CNS-TB that replicate the neuropathological and clinical features observed in human patients. These models were infected with Mycobacterium tuberculosis and facilitated investigation of molecular and cellular changes induced by the infection. Additionally, they employed advanced RNA sequencing techniques adapted for small and archived tissue samples to map gene expression alterations associated with CNS-TB progression.

Experimental treatment of these models with doxycycline, known primarily as a broad-spectrum antibiotic, yielded remarkable results. When administered alongside standard TB therapies, doxycycline markedly suppressed the production and activity of detrimental MMPs and NETs. This suppression translated into reduced neuroinflammation, preservation of brain tissue integrity, and improved vascular stability. A key consequence of enhanced vascular integrity was increased penetration of antitubercular drugs into the central nervous system, thereby bolstering the overall efficacy of treatment.

These findings are striking because they reveal doxycycline’s capacity to modulate the immune system’s damaging overreaction rather than directly targeting the tuberculosis bacteria. Such immunomodulatory capabilities of doxycycline position it as an exceptional candidate for adjunctive therapy in CNS-TB, potentially transforming the current treatment paradigm. The drug’s widespread availability, well-established safety profile, and cost-effectiveness further amplify its translational potential in global health settings burdened by tuberculosis.

Associate Professor Ong expressed optimism that these preclinical results could pave the way for rapid clinical application. “Our study suggests that doxycycline, when paired with existing TB drugs, can curtail the excessive immune responses that cause brain damage, improving survival rates,” she commented. “If validated in Phase II clinical trials, doxycycline could be widely integrated into national TB programs much faster than newly developed drugs, which often face protracted approval timelines.”

The study’s multidisciplinary authorship reflects the complexity of CNS-TB research, involving collaborations with experts from various fields and institutions. Contributors include Assistant Professor Joshua Tay from the Department of Otolaryngology at NUS Medicine, Associate Professor Andres F. Vallejo of the University of Southampton, UK, and Professor Tchoyoson Choie Cheio Lim from the Department of Neuroradiology at Singapore’s National Neuroscience Institute. This collaboration underscores the necessity of uniting infectious disease specialists, neurologists, and molecular biologists to tackle CNS-TB comprehensively.

Tuberculosis remains a dire global health threat, with over 10.8 million active cases reported worldwide in 2023 alone. Southeast Asia continues to grapple with endemic TB transmission, with Singapore registering approximately 1,100 new active cases in 2024. Notably, CNS-TB accounts for a small percentage, roughly 1 to 2 percent of all TB cases globally. However, its disproportionate mortality and morbidity make it a critical focus of medical research.

The identification of MMPs and NETs as key drivers of CNS-TB pathology opens new avenues beyond traditional antimicrobial treatment. These findings hint at a broader principle applicable to other inflammatory brain infections, where excessive immune activation contributes to neurological damage. Repurposing doxycycline as an immunomodulatory agent could therefore represent a vital step forward in managing multiple neuroinflammatory conditions.

Based on these promising results, a Phase II clinical trial has been initiated, funded by Singapore’s National Medical Research Council (NMRC). The multicenter study, spanning hospitals in Singapore, Malaysia, and Indonesia, investigates whether adding doxycycline to standard TB regimens can safely boost survival and reduce brain injury in patients with CNS-TB. The trial’s outcomes are eagerly awaited, as confirmation would provide robust clinical evidence supporting the wider adoption of this therapeutic strategy.

In conclusion, the work led by Associate Professor Ong and her team represents a paradigm shift in CNS-TB therapy, emphasizing the control of immune-mediated damage as a complement to microbial eradication. Should clinical trials corroborate these findings, doxycycline could emerge as a low-cost, scalable adjunct treatment capable of saving lives and preserving neurologic function in vulnerable populations worldwide. The potential ripple effects for managing other inflammatory brain disorders further amplify the impact of this groundbreaking research.

Subject of Research: Central Nervous System Tuberculosis treatment and immunomodulation
Article Title: MMPs and NETs are detrimental in CNS-tuberculosis with MMP Inhibition in CNS-tuberculosis mice improving survival
News Publication Date: 11-Oct-2025
Web References: http://dx.doi.org/10.1186/s12974-025-03548-7
Keywords: Tuberculosis, Central nervous system, Antibiotics, Broad spectrum antibiotics

Traditional mRNA vaccines, like those deployed globally to combat COVID-19, have been lauded for their ability to stimulate robust immune responses efficiently. However, these vaccines face two persistent challenges: they require relatively large doses of mRNA that can strain production capacity, and their effectiveness diminishes as target viruses like SARS-CoV-2 evolve new variants. This evolutionary arms race necessitates frequent vaccine reformulations, which can lag behind viral mutations.

Senior author Dr. Suresh Kuchipudi, chair of the Department of Infectious Diseases and Microbiology at Pitt Public Health, explains that the rapidly shifting genomic landscape of viruses presents a moving target. “The virus changes, moving the goal post, and updating the vaccine takes some time,” he noted. In response, his team engineered a novel mRNA platform that separates the vaccine components into two discrete RNA fragments: one encoding the antigen and the other the replicase, an enzyme necessary for amplifying the antigen-encoding sequence inside the host cells.

This decoupling permits pre-manufacture of the replicase mRNA, drastically accelerating vaccine development when new viral threats emerge. By dividing the mRNA payload, the "trans-amplifying" system can amplify the antigen sequence in vivo, leading to a potent immune response with only a fraction of the nucleic acid required by conventional vaccines. This represents a paradigm shift, as the vaccine requires approximately 40 times less mRNA, thereby reducing production costs and resource demands without compromising immunogenicity.

The researchers further refined their approach by analyzing spike-protein sequences from every known variant of SARS-CoV-2. Utilization of cutting-edge bioinformatics enabled creation of a "consensus spike protein," synthesizing the most common features across variants into a single antigen presented by the vaccine. This consensus antigen aims to elicit broadly neutralizing antibodies capable of targeting multiple viral lineages, potentially obviating the need for frequent vaccine updates.

Preclinical trials in murine models provided compelling evidence supporting the vaccine’s broad efficacy. Mice immunized with the trans-amplifying mRNA vaccine developed robust neutralizing antibodies against a spectrum of SARS-CoV-2 variants, surpassing the breadth afforded by traditional monovalent vaccines. This suggests that the vaccine could confer extended protection, even as the virus continues to evolve.

Dr. Kuchipudi highlights the implications, stating, “This has the potential for more lasting immunity that would not require updating because the vaccine has the potential to provide broad protection.” The platform’s capacity to offer durable immunity with a lower dose burden positions it as a transformative tool in pandemic preparedness and response.

Beyond SARS-CoV-2, this innovation is poised to impact vaccine development for other RNA viruses characterized by high mutation rates and pandemic potential, including avian influenza strains. The study’s authors emphasize that the lessons from their COVID-19 vaccine model are applicable to a plethora of emerging infectious diseases, potentially enabling faster, scalable responses to future outbreaks.

The collaborative effort brought together expertise across immunology, molecular biology, and computational sciences, with contributing scientists spanning both universities. This multidisciplinary approach underpinned the strategic design of the trans-amplifying vector system and the generation of a broadly reactive antigenic target.

Financial support from the Huck Institutes of the Life Sciences and the Interdisciplinary Innovation Fellowship at Penn State’s One Health Microbiome Center was instrumental to the study’s execution. This funding facilitated the integration of cutting-edge technology platforms and fostered innovation across institutional boundaries.

As the scientific community grapples with the twin challenges of viral evolution and vaccine accessibility, this new approach to mRNA vaccine design offers a beacon of hope. By reducing mRNA dosage and incorporating broad antigenic coverage, the technology promises not only to enhance global vaccine availability but also to future-proof immunizations against fast-changing pathogens.

In the wake of these promising findings, the path forward involves scaling up manufacturing and initiating human clinical trials to validate safety and efficacy. Should these efforts succeed, the trans-amplifying mRNA platform could inaugurate a new era of flexible, cost-effective vaccines—a crucial leap toward controlling not only the current pandemic but also future infectious disease threats.

Subject of Research: Not applicable

Article Title: Trans amplifying mRNA vaccine expressing consensus spike elicits broad neutralization of SARS CoV 2 variants

News Publication Date: June 3, 2025

Web References:
https://www.publichealth.pitt.edu/
https://www.psu.edu/
https://www.nature.com/articles/s41541-025-01166-1

Image Credits: University of Pittsburgh

Keywords: Vaccination, COVID-19 vaccines, Avian influenza, Vaccine development